Ph1/2 Dose Escalation and Expansion Study of BGB-10188 a PI3Kδ Inhibitor, Combined with Zanubrutinib in Patients with Mature B-Cell Malignancies and Tislelizumab in Patients with advanced Solid Tumors

Project: Research

Project Details

Project Description

NMA HREC Reference Number: 59209
NMA SSA Reference Number: SSA/59209/MonH-2020-207023(v1)
Monash Health Ref: RES-19-0000-893A
Effective start/end date19/05/2018/05/25


  • clinical trial
  • phase 1 and 2 study
  • treatment efficacy
  • treatment safety
  • Lymphoma